aromasil has been researched along with capecitabine in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Kaplow, R | 1 |
| Bari, M; Ciruelos, E; De Benedictis, E; Dittrich, C; Gaion, F; Gomez, P; Lluch, A; Luca, G; Mansutti, M; Morandi, P; Pavesi, L; Semiglazov, V; Valagussa, P; Zamagni, C; Zambetti, M | 1 |
| Blau, S; Burris, H; de Boer, RH; Ejlertsen, B; Ewertz, M; Fan, J; Hurvitz, S; Jerusalem, G; Kovalenko, E; Landherr, L; Louveau, AL; Noel-Baron, F; Özgüroglu, M; Taran, T; Yardley, DA | 1 |
| Chen, Z; Gong, C; Hu, S; Hu, X; Li, Y; Wang, B; Wang, L; Xie, Y; Yuan, P; Zhang, J; Zhang, Y; Zhao, Y | 1 |
| Robert, M; Turner, N | 1 |
| Ahn, HK; Ahn, JS; Im, SA; Im, YH; Jung, KH; Kang, SY; Kim, GM; Kim, HJ; Kim, JH; Kim, JY; Kim, SB; Kim, TY; Koh, SJ; Lee, JI; Lee, KE; Lee, KH; Lee, MH; Park, IH; Park, YH; Sohn, J | 1 |
| Chiabudini, M; Decker, T; Falkenstein, J; Hagen, V; Hahn, A; Indorf, M; Klare, P; Kurbacher, CM; Maintz, C; Potthoff, K; Runkel, E; Sent, D; Söling, U; Vehling-Kaiser, U | 1 |
| Alba, E; Alvarez, E; Antón, A; Bermejo, B; Calvo, L; Carrasco, E; Casas, M; Ciruelos, E; Corsaro, M; Csöszi, T; de la Haba-Rodriguez, J; Gal-Yam, E; Garcia-Palomo, A; Gil-Gil, M; González-Santiago, S; Kahan, Z; Lang, I; López, IÁ; Margeli, M; Martín, M; Morales, S; Muñoz, M; Murillo, L; Ramos, M; Rodrigálvarez, G; Rodríguez, CA; Ruiz-Borrego, M; Servitja, S; Zielinski, C | 1 |
2 review(s) available for aromasil and capecitabine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Innovations in antineoplastic therapy.
Topics: Adjuvants, Immunologic; Alemtuzumab; Aminoglycosides; Anastrozole; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Bile; Boronic Acids; Bortezomib; Capecitabine; Cetuximab; Decanoic Acids; Deoxycytidine; Docetaxel; Drug Approval; Estradiol; Fluorouracil; Fulvestrant; Gefitinib; Gemtuzumab; Humans; Imatinib Mesylate; Letrozole; Leuprolide; Nitriles; Oligopeptides; Organoplatinum Compounds; Oxaliplatin; Oxides; Piperazines; Polyesters; Pyrazines; Pyrimidines; Quinazolines; Taxoids; Thionucleotides; Tissue Extracts; Triazoles; United States; United States Food and Drug Administration; Vidarabine Phosphate | 2005 |
5 trial(s) available for aromasil and capecitabine
| Article | Year |
|---|---|
Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II).
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Humans; Leukopenia; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm, Residual; Neutropenia; Paclitaxel; Receptors, Estrogen; Treatment Outcome | 2012 |
Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Everolimus; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Receptor, ErbB-2; Receptors, Estrogen; Treatment Outcome | 2018 |
Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
Topics: Adult; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Drug Therapy, Combination; Female; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Middle Aged; Neoplasm Metastasis; Piperazines; Prognosis; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate | 2019 |
Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients' preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, H
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Cross-Over Studies; Estrogen Receptor alpha; Everolimus; Female; Humans; Middle Aged; Patient Preference; Prognosis; Quality of Life; Receptor, ErbB-2; Receptors, Progesterone; Survival Rate; Treatment Outcome | 2020 |
Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer: Patient-reported outcomes in the PEARL study.
Topics: Androstadienes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Capecitabine; Disease Progression; Estrogen Receptor Antagonists; Europe; Female; Fulvestrant; Health Status; Humans; Israel; Neoplasm Metastasis; Patient Reported Outcome Measures; Piperazines; Postmenopause; Progression-Free Survival; Protein Kinase Inhibitors; Pyridines; Quality of Life; Time Factors | 2021 |
2 other study(ies) available for aromasil and capecitabine
| Article | Year |
|---|---|
Treatment after Progression on Fulvestrant among Metastatic Breast Cancer Patients in Clinical Practice: a Multicenter, Retrospective Study.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Breast Neoplasms; Capecitabine; Disease Progression; Everolimus; Female; Fulvestrant; Humans; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Receptor, ErbB-2; Retrospective Studies; Risk Factors; Survival Analysis; Treatment Outcome | 2019 |
Endocrine-based therapy versus chemotherapy in advanced breast cancer.
Topics: Androstadienes; Breast Neoplasms; Capecitabine; Female; Gonadotropin-Releasing Hormone; Humans; Piperazines; Pyridines | 2019 |